Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market is anticipated to surpass US$ 51.21 billion By 2030: Data analysis by experts Growth Plus Reports

Growth Plus Reports
·6 min read
Growth Plus Reports
Growth Plus Reports

Newark, New Castle, USA, March 22, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global non-small cell lung cancer (NSCLC) therapeutics market is expected to clock US$ 51.21 billion by 2030 and to grow at a CAGR of 12.6% during the forecast period. Owing to the rise in the prevalence of the NSCLC and the rise in the R&D for cancer drug development. This exclusive information is published by Growth Plus Reports in its report titled “Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market – Global Outlook & Forecast 2022-2030”

Request a Free Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/global-non-small-cell-lung-cancer-nsclc-therapeutics-market/8173

Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Scope

Report Attribute

Details

Market size value in 2021

US$ 17.6 billion

Revenue forecast in 2030

US$ 51.21 billion

Growth Rate

CAGR of 12.6% from 2022 to 2030

Base year for estimation

2021

Forecast period

2022-2030

Historical Year

2020

Segments covered

Type, Treatment Type, and Region.

Regional scope

North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Market Drivers

The non-small cell lung cancer (NSCLC) therapeutics market is expanding significantly due to the fact that NSCLC accounts for about 80% to 85% of all instances of lung cancer worldwide. The market for non-small cell lung cancer (NSCLC) therapies is expanding due to the increased prevalence of NSCLC around the world due to rising air pollution and skyrocketing cigarette usage. The number of people with non-small cell lung cancer is growing because of the aging population. The need for NSCLC treatment is rising because of increased R&D into novel medicines such as immunotherapy, targeted therapy, and hormone therapies. The increased development of new drugs, such as biologics and inhibitors with a large drug pipeline, is also contributing significantly to the growth of the non-small cell lung cancer (NSCLC) therapies market. Additionally, the efforts being made by governments and non-governmental organizations globally to increase awareness of early cancer diagnosis and treatment are increasing the demand for non-small cell lung cancer (NSCLC) treatment.

The global non-small cell lung cancer (NSCLC) therapeutics market has been analyzed from three perspectives: Type, Treatment Type, and Region.

Excerpts from ‘By Type Segmentation’

Based on type, the global non-small cell lung cancer (NSCLC) therapeutics market is divided into:

  • Adenocarcinoma

  • Squamous Cell Carcinoma

  • Large Cell Carcinoma

  • Large Cell Neuroendocrine Tumors

Due to its higher occurrence rate than other varieties, the adenocarcinoma segment held the greatest market share in 2021. As more people smoke or have smoked in the past, there is a greater risk of getting lung adenocarcinoma, which is supporting the segment's growth. Additionally, it is more likely to manifest itself at a younger age than other types of lung cancer, enhancing the need for early diagnosis. The segment's expansion is also being aided by the availability of a strong brand portfolio for adenocarcinoma.

Excerpts from ‘By Treatment Type Segmentation’

Based on treatment type, the global non-small cell lung cancer (NSCLC) therapeutics market is segmented into:

  • Chemotherapy

  • Targeted Drug Therapy

  • Immunotherapy

In 2021, the chemotherapy segment dominated the non-small cell lung cancer (NSCLC) therapeutics market. Chemotherapy is considered the first line of therapies for a large percentage of cancers, promoting segment growth. Compared to other treatments, the chemotherapy procedure is more cost-effective in general, driving the segment growth. Furthermore, chemotherapy is being used in combination with other treatments, which is increasing the demand for chemotherapy.

Request for Customization –  https://www.growthplusreports.com/inquiry/customization/global-non-small-cell-lung-cancer-nsclc-therapeutics-market/8173

Excerpts from ‘By Region Segmentation’

Based on region, the global non-small cell lung cancer (NSCLC) therapeutics market has been segmented into:

  • North America

  • Europe

  • Asia Pacific

  • Rest of the World

North America dominated the global non-small cell lung cancer (NSCLC) therapeutics market in 2021, followed by Europe. Asia Pacific market is anticipated to grow at the fastest CAGR during the forecast period. The primary engine of regional growth is the region's increasing incidence of non-small cell lung cancer. The presence of sophisticated healthcare infrastructure and rising healthcare spending in the region is fostering regional development. Increased cancer-related R&D and the presence of numerous research institutes in the region are driving regional growth. The acceptability of non-small cell lung cancer therapies is projected to rise along with the prevalence of lung cancer risk factors, including the proportion of smokers in the general population and exposure to pollutants like asbestos and air pollution. Furthermore, it is projected that the presence of big firms in the region will promote regional growth.

Excerpts from ‘Competitive Landscape’

Some of the prominent players operating in the global non-small cell lung cancer (NSCLC) therapeutics market are:

  • Bristol-Myers Squibb Company

  • Merck & Co Inc.

  • Bayer AG

  • Novartis AG

  • Sanofi S.A.

  • Pfizer Inc.

  • Johnson & Johnson

  • F. Hoffmann-La Roche AG

  • GlaxoSmithKline plc

  • Eli Lilly and Company

  • AstraZeneca plc

  • AbbVie

  • Genentech Inc.

  • Boehringer Ingelheim GmbH

  • Teva Pharmaceutical Industries Ltd

Table of Content

  1. INTRODUCTION

    1. Market Ecosystem

    2. Timeline Under Consideration

      1. Historical Years – 2020

      2. Base Year – 2021

      3. Forecast Years – 2022 to 2030

    3. Currency Used in the Report

  2. RESEARCH METHODOLOGY 

    1. Research Approach

    2. Data Collection Methodology

    3. Data Sources

      1. Secondary Sources

      2. Primary Sources

    4. Market Estimation Approach

      1. Bottom Up

      2. Top Down

    5. Market Forecasting Model

    6. Limitations and Assumptions

  3. PREMIUM INSIGHTS

    1. Current Market Trends (COVID-19 Perspective)

    2. Key Players & Competitive Positioning (2021)

  4. MARKET DYNAMICS

    1. Drivers

    2. Restraints/Challenges

    3. Opportunities

  5. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY TYPE

    1. Adenocarcinoma

    2. Squamous Cell Carcinoma

    3. Large Cell Carcinoma

    4. Large Cell Neuroendocrine Tumors

  6. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY TREATMENT TYPE

    1. Chemotherapy

    2. Targeted Drug Therapy

    3. Immunotherapy

TOC Continued…

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8173

VALUE PROPOSITIONS RELATED TO THE REPORT:

  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

  • Comprehensive quantitative and qualitative insights at segment and sub-segment level

  • Covid 19 impact trends and perspective

  • Granular insights at global/regional/country level

  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

  • Blanket coverage on competitive landscape

  • Winning imperatives

  • Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

  • Distributor Landscape Assessment

  • Pricing Intelligence

  • Customer Base Assessment

  • Investment & Initiatives Analysis

  • 'Business Profile' of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at - https://www.growthplusreports.com/report-store

Browse related reports:

Sterilization Indicator Tape Market by Product Type (Hydrogen Peroxide Indicator Tapes, Steam Indicator Tapes), Application (Pharmaceutical & Medical Device Companies, Healthcare Facilities, Others) - Global Outlook & Forecast 2022-2030

Scoliosis Management Market by Product Type (Spinal System, Orthosis System), Disease Type (Idiopathic Scoliosis, Neuromuscular Scoliosis), Patient Group (Pediatrics, Adults) - Global Outlook & Forecast 2022-2030

Neurothrombectomy Devices Market by Device Type (Aspiration Devices, Clot Retrievers), By End-User (Hospitals, Specialty Clinics)- Global Outlook & Forecast 2022-2030

Global Neurometabolic Disorders Market Type (Gaucher's Disease, Fabry Disease, Pompe Disease), Route of Administration (Oral, Parenteral) – Global Outlook & Forecast 2022-2030

Mobility Scooters Market by Type (Small, Medium), by Wheel (2 wheels, 4 Wheels), by Battery Range (Less Than 10 Miles, 10-20 Miles), by Application (Indoor & Outdoor)– Global Outlook & Forecast 2022-2030

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

CONTACT: Manan Sethi Director, Market Insights Email: sales@growthplusreports.com 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/